Multiple Sclerosis Anti-CD20 Drug Linked to Bowel Disease Risk

(MedPage Today) -- The anti-CD20 agent rituximab was associated with a higher risk of inflammatory bowel disease (IBD) in people with relapsing-remitting multiple sclerosis (MS) compared with other disease-modifying treatments (DMTs), a population...